Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Outcome of allogeneic stem cell transplantation in patients with myelofibrosis

Bone Marrow Transplantation volume 34, pages 807–813 (2004)Cite this article

Summary:

Myelofibrosis, either de novo or following pre-existing hematologic diseases, can be cured by allogeneic hematopoietic stem cell transplantation (SCT), but SCT is associated with significant morbidity and mortality, making the choice and timing of transplantation difficult. In all, 20 patients (seven female and 13 male), with a median age of 45 years (range 22–57 years), with idiopathic myelofibrosis (n=12), post-thrombocythemic (n=3) or post-polycythemic (n=2) myeloid metaplasia or leukemic transformation (n=3), underwent allogeneic SCT at our center between 1994 and 2003. With regard to the pre-transplant presence of risk factors such as hemoglobin levels ⩽10 mg/dl, grade III marrow fibrosis or peripheral blast counts >1%, patients were divided into high- and low-risk groups. The estimated 3-year survival post transplant was 38.5% for all patients. The 3-year probability of survival within the high-risk group (n=11) characterized by the presence of at least two risk factors was 16%. Low-risk patients (n=9) with at most one risk factor had an estimated 3-year survival of 67%. Thus, previously defined risk determinants for the outcome of allogeneic transplantation for myelofibrosis may provide useful information facilitating treatment strategies. Our data suggest that transplantation should be taken into consideration before poor prognostic variables develop.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Bouroncle B, Doan CA . Myelofibrosis: clinical, hematologic and pathologic study of 110 patients. Am J Med Sci 1962; 243: 697–715.

    Article  CAS  PubMed  Google Scholar 

  2. Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255–1265.

    Article  CAS  PubMed  Google Scholar 

  3. Jacobson RJ, Salo A, Fialkow PJ . Agnogenic myeloid metaplasia: a clonal proliferation of hemopoietic stem cells with secondary myelofibrosis. Blood 1978; 5: 189–194.

    Google Scholar 

  4. Rameshwar P, Denny TN, Stein D, Gascón P . Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. J Immunol 1994; 153: 2819–2830.

    CAS  PubMed  Google Scholar 

  5. Chagraoui H, Komura E, Tulliez M et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002; 100: 3495–3503.

    Article  CAS  PubMed  Google Scholar 

  6. Cervantes F, Barosi G, Demory JL et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684–690.

    Article  CAS  PubMed  Google Scholar 

  7. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–1018.

    CAS  PubMed  Google Scholar 

  8. Cervantes F, Pereira A, Esteve J et al. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635–640.

    Article  CAS  PubMed  Google Scholar 

  9. Rozman C, Giralt M, Feliu E et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658–2663.

    Article  CAS  PubMed  Google Scholar 

  10. Hoffman R, Silverstein MN . Agnogenic myeloid metaplasia. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE (eds). Hematology: Basic Principles and Practice, 2nd edn. Churchill Livingstone: New York, USA, 1995, pp 1160–1174.

    Google Scholar 

  11. Anderson JE, Sale G, Appelbaum FR et al. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997; 98: 1010–1016.

    Article  CAS  PubMed  Google Scholar 

  12. Guardiola P, Anderson JE, Bandini G et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European group for blood and marrow transplantation, société française de greffe de moelle, gruppo italiano per il trapianto midollo osseo, and Fred Hutchinson cancer research center. Blood 1999; 93: 2831–2838.

    CAS  PubMed  Google Scholar 

  13. Deeg J, Gooley TA, Flowers ME et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912–3918.

    Article  CAS  PubMed  Google Scholar 

  14. Laszlo J . Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 1975; 12: 409–432.

    CAS  PubMed  Google Scholar 

  15. Murphy S, Peterson P, Iland H, Laszlo J . Experience of the polycythemia study group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29–39.

    CAS  PubMed  Google Scholar 

  16. Thiele J, Kvasnicka HM, Fischer R . Histochemistry and morphometry on bone marrow biopsies in chronic myeloproliferative disorders – aids to diagnosis and classification. Ann Hematol 1999; 78: 495–506.

    Article  CAS  PubMed  Google Scholar 

  17. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipient of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  18. Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation. N Engl J Med 1975; 292: 832–843.

    Article  CAS  PubMed  Google Scholar 

  19. Elmaagacli AH, Runkel K, Steckel N et al. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Bone Marrow Transplant 2001; 27: 809–815.

    Article  CAS  PubMed  Google Scholar 

  20. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.

    Article  Google Scholar 

  21. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087.

    Article  CAS  PubMed  Google Scholar 

  22. Ottinger HD, Ferencik S, Beelen DW et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors. Blood 2003; 102: 1131–1137.

    Article  CAS  PubMed  Google Scholar 

  23. Soll E, Massumoto C, Clift RA et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 1995; 86: 4667–4673.

    CAS  PubMed  Google Scholar 

  24. Cervantes F, Rovira M, Urbano-Ispizua A et al. Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplant 2000; 26: 697–699.

    Article  CAS  PubMed  Google Scholar 

  25. Anderson JE, Trefferi A, Craig F et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 2001; 98: 586–593.

    Article  CAS  PubMed  Google Scholar 

  26. Tanner ML, Hoh CK, Bashey A et al. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Bone Marrow Transplant. 2003; 32: 581–585.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstr. 55, Essen, 45122, Germany

    M Ditschkowski, D W Beelen, R Trenschel, M Koldehoff & A H Elmaagacli

Authors
  1. M Ditschkowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D W Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Trenschel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Koldehoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A H Elmaagacli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Ditschkowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ditschkowski, M., Beelen, D., Trenschel, R. et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 34, 807–813 (2004). https://doi.org/10.1038/sj.bmt.1704657

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704657

Keywords

This article is cited by

Search

Advanced search

Quick links